Sar-bbn CU-64 clinical trials
Also written 64Cu-SAR-BBN.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses sar-bbn CU-64 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Clarity Pharmaceuticals Ltd (2) · St Vincent's Hospital, Sydney (1)
Often tested with
Tested in the same studies.
Sar-bbn CU-67 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses sar-bbn CU-64 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)CompletedPhase 2Clarity Pharmaceuticals LtdNCT05407311Written as 64Cu-SAR-BBNHow we know
- 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)TerminatedPhase 1/2Clarity Pharmaceuticals LtdNCT05633160Written as 64Cu-SAR-BBNHow we know
- Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)CompletedPhase 2St Vincent's Hospital, SydneyNCT05613842Written as Copper-64 labelled SAR-BombesinHow we know
Codes
What other systems call sar-bbn CU-64 · ClinicalTrials.gg INT018686
- UNII (FDA) ZG72H4J6MKSAR-BBN CU-64One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZG72H4J6MK | SAR-BBN CU-64 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.